Pancreatic cancer in obesity: Epidemiology, clinical observations, and basic mechanisms

Nicholas Zyromski, Patrick B. White

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Obesity, now a worldwide epidemic, causes myriad medical problems. One of the most significant obesity-related problems is the well-recognized relationship between obesity and various malignancies, including pancreatic cancer. Pancreatic cancer is a devastating disease - the annual death rate nearly approximates its incidence. While surgical extirpation provides the best chance at long term survival, systemic therapy is largely ineffective: even those patients undergoing successful operative resection have only approximately 20% 5-year survival. These poor outcomes are largely a consequence of poor understanding of tumor biology. Clearly, identification of novel treatment strategies is of paramount importance; investigation of pancreatic cancer biology from the novel aspect of obesity offers the potential to identify unique therapeutic targets. This manuscript reviews the epidemiology, clinical findings, and putative basic science mechanisms underlying obesity-related pancreatic cancer.

Original languageEnglish
Pages (from-to)470-478
Number of pages9
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume11
Issue number5
StatePublished - Jun 2011

Fingerprint

Pancreatic Neoplasms
Epidemiology
Obesity
Survival
Neoplasms
Therapeutics
Mortality
Incidence

Keywords

  • Adipokines
  • Adiponectin
  • B-lymphocytes
  • Leptin
  • Obesity
  • Pancreatic cancer
  • Tumor immunology

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Pharmacology

Cite this

Pancreatic cancer in obesity : Epidemiology, clinical observations, and basic mechanisms. / Zyromski, Nicholas; White, Patrick B.

In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 11, No. 5, 06.2011, p. 470-478.

Research output: Contribution to journalArticle

@article{e9a5d78b7eed45b6966608b0927bdfdc,
title = "Pancreatic cancer in obesity: Epidemiology, clinical observations, and basic mechanisms",
abstract = "Obesity, now a worldwide epidemic, causes myriad medical problems. One of the most significant obesity-related problems is the well-recognized relationship between obesity and various malignancies, including pancreatic cancer. Pancreatic cancer is a devastating disease - the annual death rate nearly approximates its incidence. While surgical extirpation provides the best chance at long term survival, systemic therapy is largely ineffective: even those patients undergoing successful operative resection have only approximately 20{\%} 5-year survival. These poor outcomes are largely a consequence of poor understanding of tumor biology. Clearly, identification of novel treatment strategies is of paramount importance; investigation of pancreatic cancer biology from the novel aspect of obesity offers the potential to identify unique therapeutic targets. This manuscript reviews the epidemiology, clinical findings, and putative basic science mechanisms underlying obesity-related pancreatic cancer.",
keywords = "Adipokines, Adiponectin, B-lymphocytes, Leptin, Obesity, Pancreatic cancer, Tumor immunology",
author = "Nicholas Zyromski and White, {Patrick B.}",
year = "2011",
month = "6",
language = "English",
volume = "11",
pages = "470--478",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Pancreatic cancer in obesity

T2 - Epidemiology, clinical observations, and basic mechanisms

AU - Zyromski, Nicholas

AU - White, Patrick B.

PY - 2011/6

Y1 - 2011/6

N2 - Obesity, now a worldwide epidemic, causes myriad medical problems. One of the most significant obesity-related problems is the well-recognized relationship between obesity and various malignancies, including pancreatic cancer. Pancreatic cancer is a devastating disease - the annual death rate nearly approximates its incidence. While surgical extirpation provides the best chance at long term survival, systemic therapy is largely ineffective: even those patients undergoing successful operative resection have only approximately 20% 5-year survival. These poor outcomes are largely a consequence of poor understanding of tumor biology. Clearly, identification of novel treatment strategies is of paramount importance; investigation of pancreatic cancer biology from the novel aspect of obesity offers the potential to identify unique therapeutic targets. This manuscript reviews the epidemiology, clinical findings, and putative basic science mechanisms underlying obesity-related pancreatic cancer.

AB - Obesity, now a worldwide epidemic, causes myriad medical problems. One of the most significant obesity-related problems is the well-recognized relationship between obesity and various malignancies, including pancreatic cancer. Pancreatic cancer is a devastating disease - the annual death rate nearly approximates its incidence. While surgical extirpation provides the best chance at long term survival, systemic therapy is largely ineffective: even those patients undergoing successful operative resection have only approximately 20% 5-year survival. These poor outcomes are largely a consequence of poor understanding of tumor biology. Clearly, identification of novel treatment strategies is of paramount importance; investigation of pancreatic cancer biology from the novel aspect of obesity offers the potential to identify unique therapeutic targets. This manuscript reviews the epidemiology, clinical findings, and putative basic science mechanisms underlying obesity-related pancreatic cancer.

KW - Adipokines

KW - Adiponectin

KW - B-lymphocytes

KW - Leptin

KW - Obesity

KW - Pancreatic cancer

KW - Tumor immunology

UR - http://www.scopus.com/inward/record.url?scp=79958084567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958084567&partnerID=8YFLogxK

M3 - Article

C2 - 21492072

AN - SCOPUS:79958084567

VL - 11

SP - 470

EP - 478

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 5

ER -